Association and linkage analysis of candidate genes GRP, GRPR, CRHR1, and TACR1 in panic disorder

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 1, 2009, Pages 65-73

  Hodges, Laura M ^a   Weissman, Myrna M ^b   Haghighi, Fatemeh ^b   Costa, Ramiro ^b   Bravo, Oscar ^a   Evgrafov, Oleg ^c   Knowles, James A ^c   Fyer, Abby J ^b   Hamilton, Steven P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b New York State Psychiatric Institute ^*  (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Corticotropin releasing hormone; Gastrin releasing peptide; Neuropeptide; SNP; Tachykinin

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; TACHYKININ RECEPTOR;

ALLELE; ARTICLE; GENE LOCUS; GENETIC ANALYSIS; GENETIC LINKAGE; HUMAN; MAJOR CLINICAL STUDY; PANIC; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; GASTRIN-RELEASING PEPTIDE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE (GENETICS); PANIC DISORDER; RECEPTORS, BOMBESIN; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, TACHYKININ;

EID: 58849151760     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30773     Document Type: Article

References (91)

1. Aguiar MS, Brandao ML. 1996. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol Behav 60:1183-1186.
2. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT. 1991. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 103:227-232.
3. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. 2004. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 29:208-218.
4. Boyce S, Smith D, Carlson E, Hewson L, Rigby M, O'Donnell R, Harrison T, Rupniak NM. 2001. Intra-amygdala injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal vocalisations in guineapigs. Neuropharmacology 41:130-137.
5. Brodin E, Rosen A, Schott E, Brodin K. 1994. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions. Neuropeptides 26:253-260.
6. Butler PD, Weiss JM, Stout JC, Nemeroff CB. 1990. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci 10:176-183.
7. Cheeta S, Tucci S, Sandhu J, Williams AR, Rupniak NMJ, File SE. 2001. Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 915:170-175.
8. Chen X, Levine L, Kwok PY. 1999. Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 9:492-498.
9. Commons KG, Valentino RJ. 2002. Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. J Comp Neurol 447:82-97.
10. Conley RK, Cumberbatch MJ, Mason GS, Williamson DJ, Harrison T, Locker K, Swain C, Maubach K, O'Donnell R, Rigby M, Hewson L, Smith D, Rupniak NM. 2002. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 22:7730-7736.
11. Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W, Gold LH. 1999. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 835:1-9.
12. Cottingham RW Jr, Idury RM, Schaffer AA. 1993. Faster sequential genetic linkage computations. Am J Hum Genet 53:252-263.
13. Crowe RR, Noyes R Jr, Pauls DL, Slymen D. 1983. A family study of panic disorder. Arch Gen Psychiatry 40:1065-1069.
14. Evans DM, Marchini J, Morris AP, Cardon LR. 2006. Two-stage two-locus models in genome-wide association. PLoS Genet 2(9):e157. DOI: 10.1371/journal.pgen.0020157.
15. Fehder WP, Sachs J, Uvaydova M, Douglas SD. 1997. Substance P as an immune modulator of anxiety. Neuroimmunomodulation 4:42-48.
16. File SE. 1997. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 58:747-752.
17. Flood JF, Morley JE. 1988. Effects of bombesin and gastrin-releasing peptide on memory processing. Brain Res 460:314-322.
18. Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De FC, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L. 2001. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21:8188-8197.
19. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, Pich EM, Nilsson LG, Bani M, Langstrom B, Fredrikson M. 2005. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58:132-142.
20. Fyer AJ, Weissman MM. 1999. Genetic linkage study of panic: Clinical methodology and description of pedigrees. Am J Med Genet (Neuropsychiatr Genet) 88:173-181.
21. Fyer AJ, Hamilton SP, Durner M, Haghighi F, Heiman GA, Costa R, Evgrafov O, Adams P, de Leon AB, Taveras N, Klein DF, Hodge SE, Weissman MM, Knowles JA. 2006. A third-pass genome scan in panic disorder: Evidence for multiple susceptibility loci. Biol Psychiatry 60:388-401.
22. Garrido MM, Martin S, Ambrosio E, Fuentes JA, Manzanares J. 1998. Role of corticotropin-releasing hormone in gastrin-releasing peptide-mediated regulation of corticotropin and corticosterone secretion in male rats. Neuroendocrinology 68:116-122.
23. Garrido MM, Manzanares J, Fuentes JA. 1999. Hypothalamus, anterior pituitary and adrenal gland involvement in the activation of adrenocorticotropin and corticosterone secretion by gastrin-releasing peptide. Brain Res 828:20-26.
24. Garrido MM, Fuentes JA, Manzanares J. 2002. Gastrin-releasing peptide mediated regulation of 5-HT neuronal activity in the hypothalamic paraventricular nucleus under basal and restraint stress conditions. Life Sci 70:2953-2966.
25. Greenberg DA, Abreu P, Hodge SE. 1998. The power to detect linkage in complex disease by means of simple LOD-score analyses. Am J Hum Genet 63:870-879.
26. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrie P. 2002. 4-(2-Chloro-4-methoxy-5-methylphenyl)- N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]5-methyl-N-(2-propynyl)- 1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345.
27. Haddjeri N, Blier P. 2001. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 50:191-199.
28. Hamilton SP, Heiman GA, Haghighi F, Mick S, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA. 1999. Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. Psychiatr Genet 9:1-6.
29. Hamilton SP, Fyer AJ, Durner M, Heiman GA, Baisre de LA, Hodge SE, Knowles JA, Weissman MM. 2003. Further genetic evidence for a panic disorder syndrome mapping to chromosome13q. Proc Natl Acad Sci USA 100:2550-2555.
30. Hasenohrl RU, Souza-Silva MAD, Nikolaus S, Tomaz C, Brandao ML, Schwarting RKW, Huston JP. 2000. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 34:272-280.
31. Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF. 1992. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 581:190-197.
32. Heinrichs SC, Lapsansky J, Lovenberg TW, De Souza EB, Chalmers DT. 1997. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 71:15-21.
33. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, Nagayama H. 2000. Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 33:189-193.
34. Hodge SE, Abreu PC, Greenberg DA. 1997. Magnitude of type I error when single-locus linkage analysis is maximized over models: A simulation study. Am J Hum Genet 60:217-227.
35. Horvath S, Xu X, Laird NM. 2001. The family based association test method: Strategies for studying general genotype-phenotype associations. Eur J Hum Genet 9:301-306.
36. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. 2006. The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. Arch Gen Psychiatry 63: 415-424.
37. Knowles JA, Fyer AJ, Vieland VJ, Weissman MM, Hodge SE, Heiman GA, Haghighi F, de Jesus GM, Rassnick H, Preud'homme-Rivelli X, Austin T, Cunjak J, Mick S, Fine LD, Woodley KA, Das K, Maier W, Adams PB, Freimer NB, Klein DF, Gilliam TC. 1998. Results of a genome-wide genetic screen for panic disorder. Am J Med Genet (Neuropsychiatr Genet) 81:139-147.
38. Koob GF. 1996. Drug addiction: The yin and yang of hedonic homeostasis. Neuron 16:893-896.
39. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
40. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. 1996. Parametric and nonparametric linkage analysis: A unified multipoint approach. Am J Hum Genet 58:1347-1363.
41. Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F. 2003. Treatment of depression with the CRH-1-receptor antagonist R121919: Endocrine changes and side effects. J Psychiatr Res 37:525-533.
42. Kunzel HE, Ising M, Zobel AW, Nickel T, Ackl N, Sonntag A, Holsboer F, Uhr M. 2005. Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. J Psychiatr Res 39:173-177.
43. Laird NM, Horvath S, Xu X. 2000. Implementing a unified approach to family-based tests of association. Genet Epidemiol 19(Suppl 1):S36-S42.
44. Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL, Godonis HE, Ren SX, Yan XX, Arneric SP, Robertson DW, Hartig PR, Grossman S, Trainor GL, Taub RA, Zaczek R, Gilligan PJ, McElroy JF. 2004. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5 -a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. J Pharmacol Exp Ther 309:293-302.
45. Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A. 1995. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 59:229-239.
46. Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F. 1999. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33:153-163.
47. Livak KJ. 1999. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14:143-149.
48. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau JL. 1996. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309:195-200.
49. Mansbach RS, Brooks EN, Chen YL. 1997. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323:21-26.
50. Marquez M, Segui J, Garcia L, Canet J, Ortiz M. 2001. Is panic disorder with psychosensorial symptoms (depersonalization-derealization) a more severe clinical subtype? J Nerv Ment Dis 189:332-335.
51. Martins MR, Reinke A, Valvassori SS, Machado RA, Quevedo J, Schwartsmann G, Roesler R. 2005. Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. Peptides 26:2525-2529.
52. Merali Z, McIntosh J, Kent P, Michaud D, Anisman H. 1998. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. J Neurosci 18:4758-4766.
53. Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A. 2001. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25:585-600.
54. Nussdorfer GG, Malendowicz LK. 1998. Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 19:949-968.
55. Pauls DL, Bucher KD, Crowe RR, Noyes R Jr. 1980.Agenetic study of panic disorder pedigrees. Am J Hum Genet 32:639-644.
56. Radulovic J, Ruhmann A, Liepold T, Spiess J. 1999. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: Differential roles of CRF receptors 1 and 2. J Neurosci 19:5016-5025.
57. Risch N, Merikangas K. 1996. The future of genetic studies of complex human diseases. Science 273:1516-1517.
58. Roesler R, Meller CA, Kopschina MI, Souza DO, Henriques JAP, Schwartsmann G. 2003. Intrahippocampal infusion of the bombesin/gastrin-releasing peptide antagonist RC-3095 impairs inhibitory avoidance retention. Peptides 24:1069-1074.
59. Roesler R, Kopschina MI, Rosa RM, Henriques JAP, Souza DO, Schwartsmann G. 2004a. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol 486:35-41.
60. Roesler R, Lessa D, Venturella R, Vianna MRM, Luft T, Henriques JAP, Izquierdo I, Schwartsmann G. 2004b. Bombesin/gastrin-releasing peptide receptors in the basolateral amygdala regulate memory consolidation. Eur J Neurosci 19:1041-1045.
61. Rosen A, Brodin K, Eneroth P, Brodin E. 1992. Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the peri-aqueductal grey and limbic regions of rat brain. Acta Physiol Scand 146:341-348.
62. Rupniak NMJ, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A. 2000. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39: 1413-1421.
63. Sahuque LL, Kullberg EF, McGeehan AJ, Kinder JR, Hicks MP, Blanton MG, Janak PH, Olive MF. 2006. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: Role of CRF receptor subtypes. Psychopharmacology (Berl) 186:122-132.
64. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ. 2001. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98:1912-1917.
65. Santarelli L, Gobbi G, Blier P, Hen R. 2002. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1). J Clin Psychiatry 63(Suppl 11):11-17.
66. Santo-Yamada Y, Yamada K, Wada K. 2001. Posttraining administration of gastrin-releasing peptide improves memory loss in scopolamine- and hypoxia-induced amnesic mice. Physiol Behav 74:139-143.
67. Schaffer AA, Gupta SK, Shriram K, Cottingham RW Jr. 1994. Avoiding recomputation in linkage analysis. Hum Hered 44:225-237.
68. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. 1996. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 739:70-78.
69. Shumyatsky GP, Tsvetkov E, Malleret G, Vronskaya S, Hatton M, Hampton L, Battey JF, Dulac C, Kandel ER, Bolshakov VY. 2002. Identification of a signaling network in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear. Cell 111:905-918.
70. Skutella T, Criswell H, Moy S, Probst JC, Breese GR, Jirikowski GF, Holsboer F. 1994a. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport 5:2181-2185.
71. Skutella T, Montkowski A, Stohr T, Probst JC, Landgraf R, Holsboer F, Jirikowski GF. 1994b. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol 14:579-588.
72. Skutella T, Probst JC, Renner U, Holsboer F, Behl C. 1998. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 85:795-805.
73. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF. 1998. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102.
74. Smoller JW, Yamaki LH, Fagerness JA, Biederman J, Racette S, Laird NM, Kagan J, Snidman N, Faraone SV, Hirshfeld-Becker D. 2005. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 57:1485-1492.
75. Starcevic V, Kellner R, Uhlenhuth EH, Pathak D. 1993. The phenomenology of panic attacks in panic disorder with and without agoraphobia. Compr Psychiatry 34:36-41.
76. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. 1994. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior. J Neurosci 14:2579-2584.
77. Stockmeier CA, Shi X, Konick L, Overholser JC, Jurjus G, Meltzer HY, Friedman L, Blier P, Rajkowska G. 2002. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport 13:1223-1227.
78. Swerdlow NR, Geyer MA, Vale WW, Koob GF. 1986. Corticotropin-releasing factor potentiates acoustic startle in rats: Blockade by chlordiazepoxide. Psychopharmacology (Berl) 88:147-152.
79. Teixeira RM, Santos ARS, Ribeiro SJ, Calixto JB, Rae GA, De Lima TCM. 1996. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7-14.
80. Terwilliger JD, Ott J. 1992. A haplotype-based 'haplotype relative risk' approach to detecting allelic associations. Hum Hered 42:337-346.
81. Tharmalingam S, King N, De L V, Rothe C, Koszycki D, Bradwejn J, Macciardi F, Kennedy JL. 2006. Lack of association between the corticotrophin-releasing hormone receptor 2 gene and panic disorder. Psychiatr Genet 16:93-97.
82. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W. 1998. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-166.
83. Valentino RJ, Commons KG. 2005. Peptides that fine-tune the serotonin system. Neuropeptides 39:1-8.
84. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, Carey GJ, Coffin VL. 2002. The gerbil elevated plus-maze II: Anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27:371-379.
85. Vieland VJ, Goodman DW, Chapman T, Fyer AJ. 1996. New segregation analysis of panic disorder. Am J Med Genet 67:147-153.
86. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu H-G, Joyce PR, Karam EG, Lee C-K, Lellouch J, Lepine J-P, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H-U, Yeh E-K. 1997. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54:305-309.
87. Weissman MM, Fyer AJ, Haghighi F, Heiman G, Deng Z, Hen R, Hodge SE, Knowles JA. 2000. Potential panic disorder syndrome: Clinical and genetic linkage evidence. Am J Med Genet 96:24-35.
88. Weissman MM, Gross R, Fyer A, Heiman GA, Gameroff MJ, Hodge SE, Kaufman D, Kaplan SA, Wickramaratne PJ. 2004. Interstitial cystitis and panic disorder: A potential genetic syndrome. Arch Gen Psychiatry 61:273-279.
89. Xiao M, Latif SM, Kwok PY. 2003. Kinetic FP-TDI assay for SNP allele frequency determination. Biotechniques 34:190-197.
90. Yang M, Farrokhi C, Vasconcellos A, Blanchard RJ, Blanchard DC. 2006. Central infusion of ovine CRF (oCRF) potentiates defensive behaviors in CD-1 mice in the Mouse Defense Test Battery (MDTB). Behav Brain Res 171:1-8.
91. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 34:171-181.